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PERSPECTIVES IN CLINICAL NEPHROLOGY
Endothelin in renal pathophysiology: From experimental to
therapeutic application
Endothelin was discovered as recently as 1988 as a potent
vasoconstrictor peptide [1]. This discovery has opened up a new
proliferative field in biomedical research. Increased expression of
endothelin in various renal diseases, the injurious actions of
endothelin on renal cells in vitro, and the beneficial effects of
specific blockers of endothelin in experimental renal disease have
created a very attractive pathophysiological paradigm in renal
medicine, as was reviewed in this journal previously [2—6]. How-
ever, at the same time, renal disease is a multifactorial process,
and only little information is available on interactions of endo-
thelin with other pathophysiological factors in the kidney. Fur-
thermore, it is unclear whether the experiments with endothelin
receptor blockers also prevent structural damage, and whether
results of such experiments can be extrapolated to the human
situation. The aim of the present review is to place the endothelin
concept, as it was introduced in this journal, in a clinical perspec-
tive. In the first part we will briefly discuss the current status of
this endothelin concept, and in the second part we will discuss its
caveats and clinical applicability.
Rationale for the endothelin concept
Endothelin-system in the kidney
The endothelins encompass a family of three isopeptides, which
are all cleaved from proendothelins (Big ET's) by an endothelin
converting enzyme [1, 7], The kidney is an important organ for
endothelin synthesis. The most important isopeptide is endothe-
un-i (ET-1), which is produced by endothelial, mesangial, gb-
merular epithelial and medullary collecting duct cells [8—111.
Although studies in rats and cell cultures also demonstrated ET-3
production in gbomerular epithelial cells and medullaiy collecting
duct cells [8, 10], ET-3 production could not be demonstrated in
the human kidney [12]. In normal kidneys ET-i immunostaining is
confined to the endothelium of the intrarenal blood vessels and
the glomerulus [12]. ET-1 synthesis is tightly regulated at the
transcriptional level. Importantly, various humoral factors in-
volved in glomerular injury, such as thrombin, hypoxia, transform-
ing growth factor-13 and angiotensin II can stimulate ET-l synthe-
sis [1, 13, 14]. ET-1 interacts with type A (ETa) and type B (ETb)
receptors. In the human kidney the ETh receptor predominates
over the ETa receptor, the ETa receptor being localized in the
vasculature and the ETh receptor in renal tubuli and medulla [15,
16]. ET-1 forms very strong ligand-receptor complexes that are
rapidly internalized and inactivated [17], resulting in a very short
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half-life of circulating ET-1 [18, 19]. It is therefore generally
believed that ET-1 exerts its actions in the kidney mainly as an
autocrine/paracrine factor, which is also suggested by the fact that
sites of endothelin-synthesis and endothelin-receptors are closely
linked [12]. Despite its short circulating half-life the biological
effects of ET-1 usually are sustained for a long period of time.
Receptor internalization followed by externalization of new or
recycled receptors may contribute to these prolonged biological
effects [20, 21]. Multiple intracellular signal transduction systems
have been linked to the endothelin receptors (Fig. 1) [22]. The
most important one is probably activation of phospholipase C and
the inositol-phosphate pathway leading to sustained elevations of
intracellular calcium. It has been suggested that the plateau phase
of the intracellular calcium response may also play a role in the
prolonged responses to endothelin [23]. The putative actions of
ET-1 in the kidney include stimulation of renal cell growth
[24—26], cell differentiation during organogenesis [27], vasocon-
striction [28 —30], and inhibition of sodium and water reabsorption
in the renal medulla [31, 32]. The relevance of the endothelin
system for the kidney under basal conditions is not well estab-
lished. Usually no or only little effects on renal blood flow and
sodium excretion have been observed under basal conditions
during intrarenal endothelin blockade in animals [33—351, while
one study demonstrated an increase in renal blood flow and
sodium excretion [36].
Pharmacological antagonism of the endothelin system
A major advance in our understanding of the renal endothelin
system was made by the development of pharmacological antag-
onists of ET-1. Currently drug development in this area focuses on
reducing endogenous ET-1 production by inhibition of endothelin
converting enzyme (ECE), and antagonizing binding of ET-1 to its
receptor.
ECE is a pH neutral metalboprotease that is inhibited by
phosphoramidon but is insensitive to related metalboprotease
inhibitors such as thiorpan [371. In agreement, phosphoramidon
inihibits release of ET-1 from endothelial cells and antagonizes
the pharmacological effects of exogenously administered ET-1 in
a variety of animal protocols as well as in the human forearm [38,
39]. However, phosphoramidon is also a potent inhibitor of NEP
24.11, an enzyme which is widely distributed in the body and
which is involved in the clearance of ET-1 as well as in the
metabolism of bradykinins and ANP [23]. These actions challenge
the use of phosphoramidon as a selective ECE-inhibitor. There-
fore, several pharmaceutical companies are developing more
selective ECE-inhibitors based on phosphoramidon or big ET-1
analogues [40—42].
The development of ET receptor blockers has been established
on development of peptide analogues. The discovery of BQ123, a
cyclic pentapeptide which selectively inhibits the ETa receptor,
1827
ET-i Big-FT-i
cytosol
ET-1
PTK PKC
1828 Rabelink et at: Endothelin
Fig. 1. Schematic representation of signal transduction and targets for antagonism of endothelin. Big ET-1, secreted by the target cell or derived from the
circulation, is converted by endothelin converting enzyme (ECE) to activate ET-1. Arrow 1 indicates the site of action of ECE inhibitors. ET-1
subsequently binds to the receptor (ETr) and activates phospholipase C via a pertussis-toxin insensitive G-protein (G), resulting in the formation of
inosital triphosphate (1P3). This 1P3 formation will stimulate intracellular calcium mobilization, which activates L-type calcium channels, thus
contributing to sustained increments in intracellular calcium. ETr activation perhaps may also directly open these channels. The receptor can be blocked
by receptor antagonists (arrow 2), and the L-type calcium channels by calcium channel blockers (arrow 3). It has been postulated that these signal
transduction pathways are mainly involved in the contractile actions of ET-1. ET receptor activation will also stimulate protein kinase C (PKC), and
several protein tyrosine kinases (PTK). These cytosolic effectors in turn alter gene expression, and have been implicated in the mitogenic actions of ET-1,
while PKC may perhaps also contribute to vasoconstriction by phosphorylation of myosin light chains. Finally, ET receptor activation can stimulate
arachidonic metabolism via activation of phospholipase A2 (not shown).
Table 1. Orally available ET-receptor antagonists in clinical drug
development
Compound Selectivity Company
Bosentan mixed ETA/ETB Hoffman-LaRoche
SB 209670 mixed ETA/ETB SmithKline Beecham
BMS 182874 ETA Bristol-Myers Squibb
LU 135252 ETA Knoll
A-127722 ETA Abbott
signified a major progression in this field [43]. Later hexapeptides
were developed based upon the C-terminal portion of the endo-
thelins, which could block both the ETa and the ETb receptor. A
major problem with these peptide-analogues is that they are not
effective via the oral route. Moreover, binding of peptide ana-
logues to ET receptors is less stable than the binding of native
endothelins to these receptors [44], which may render these
antagonists less effective. This explains the high dosages required
in experimental studies. These characteristics and the high costs of
the peptide analogues make these receptor antagonists less suit-
able for use in humans. Only recently have non-peptide ET
receptor antagonists been introduced, some of which are also
orally active (Table 1). Drug development in this area is rapidly
evolving and by the time this review is being published new
compounds probably will have been disclosed.
Several other ways to interfere with the renal endothelin system
are under investigation as well. For example, there is increasing
evidence that ET-1 may also interact with ATP-sensitive potas-
sium channels [45—47]. This could constitute a target for future
pharmacological antagonism of ET-1. Therapeutic strategies
based on functional antagonism of ET-1 induced constrictor or
growth promoting effects may emerge as well. For example, the
natriuretic peptides such as ANP and BNP, as well as inhibitors of
their degradation may directly or indirectly oppose ET-1 under
certain conditions [48, 49]. Functional antagonism of ET-1 by
nitrovasodilators or stimulation of endogenous nitric oxide has
also been reported, although this mechanism appears to be less
efficacious in the human kidney [30, 50].
Endothelin as a pathophysiological factor in renal disease
Elevated plasma levels of ET-1, secondary to decreased renal
clearance of the peptide, have been reported in many renal
diseases [51—53]. In addition, renal production of ET-1 may be
enhanced in renal diseases, even when circulating ET-1 is not
elevated [54—57]. Both circulating levels of ET-1 as well as locally
produced ET-1 can cause long-lasting increments in renal vascular
resistance via preglomerular and postglomerular constriction [58—
61]. In addition, ET-1 can cause mesangial contraction and thus
reduce the ultrafiltration coefficient [28]. These vasoconstrictive
effects of FT-i were confirmed in vivo in humans, where infusion
of ET-1, attaining pathophysiological increments in plasma ET-1
levels, caused profound and prolonged vasoconstriction [29, 62].
ET-1 may thus play a role in the development of acute renal
failure, which most commonly arises due to renal vasoconstriction
and subsequent ischemic necrosis of renal tubules [63]. In agree-
ment with this hypothesis, plasma levels of ET-1 and/or renal
expression of ET-i have been reported to be elevated in acute
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ischemic renal failure [51], in septicemia [64] and during admin-
istration of cyclosporine and radiocontrast agents [65—67]. More-
over, acute inhibition of the actions of ET-1 by administration of
antibodies against ET-1 or endothelin-receptor blockers reduce
renal vasoconstriction and glomerular dysfunction in experimen-
tal renal ischemia [68—72], and can decrease mortality among
treated animals even when administered 24 hours after the
ischemia [731. Similarly, endothelin-receptor blockers also could
restore cyclosporine-induced changes in renal hemodynamics and
blood pressure [71, 72, 74].
Endothelin may also contribute to progressive structural renal
damage in chronic kidney disease. In rats with partial renal mass
(by ablation), urinary excretion of endothelin was markedly
enhanced [55—57] and it increased in time parallel to the devel-
opment of glomeruloscierosis. Similarly, patients with chronic
renal disease demonstrate significantly elevated urinary ET-1
excretion [75]. Development of glomerulosclerosis in the renal
ablation model, as well as in models such as puromycin-nephrosis
[761, and streptozotocin-induced diabetes [77] was also accompa-
nied by increased ET-1 gene expression in the kidney, suggesting
that ET-1 may also play a role in the progression of chronic renal
failure, Indeed, in analogy to other vasoactive peptides, such as
angiotensin II, ET-1 has been demonstrated to stimulate mesan-
gial cell growth in vitro [24—26] as well as in vivo [78] and to
increase the expression of extracellular matrix proteins such as
collagen and laminin [79, 801. Both compensatory renal growth
and matrix expansion are characteristic of progressive renal
disease. In addition, several other factors that have been impli-
cated in the pathogenesis of progressive renal disease, such as
angiotensin II, transforming growth factor-/3, insulin-like growth
factor and basic fibroblast growth factor, stimulate the production
of ET-1 [13, 14]. A role for endothelin in the pathogenesis of
chronic progressive renal disease is reinforced by observations
showing that endothelin-receptor blockade could reduce the
development of proteinuria and glomerular lesions in the renal
ablation model [81, 821 as well as in experimental immune
complex nephritis [831. These results still require further verifica-
tion, but clearly indicate an exciting therapeutic application of the
endothelin concept.
Renal disease is also frequently complicated by hypertension,
which has been associated with accelerated development of
further renal injury. Because of its vasoconstrictor action and its
effects on vascular hypertrophy, ET-1 has also been implicated
in the pathogenesis of hypertension and/or the maintenance of
hypertension. Persistent hypertension may occur following infu-
sion of ET-1 in vivo and as a result of endothelin secreting tumors
[84, 851. In addition, the preliminary data on systemic ET-receptor
blockade in humans show vasodilatiori and reduction of blood
pressure, suggesting that ET-1 plays a role in the maintenance of
vascular tone [86]. In some animal models of hypertension, such
as the sodium-deplete squirrel and the DOCA salt hypertensive
rat, ET receptor blockade caused marked reductions in blood
pressure [87, 88]. In the latter model this was also associated with
regression of vascular hypertrophy. On the other hand, the effects
of ET antagonism in other experimental models of hypertension,
notably the SHR, are less clear [reviewed in 89]. The possible role
ET-1 as a hypertensive factor in renal disease is not yet well
established. However, administration of endothelin receptor
blockers in experimental models of renal disease, such as the renal
ablation model and chronic administration of cyclosporine [74,
81], causes large reductions in arterial blood pressure, suggesting
that hypertension in some models of renal disease may be largely
ET-dependent.
Endothelin receptor blockade in human renal disease
The renal endothelin system offers an attractive pathophysio-
logical paradigm by implicating a new pathophysiological factor in
the development of both acute and chronic progressive renal
disease. The final answer to whether or not ET receptor blockers
will be beneficial in human renal disease can be obtained only by
short-term and long-term studies in patients. However, before
reaching that stage, several issues relevant for our general expec-
tations concerning the clinical applicability of the endothelin
concept in renal medicine should be considered. First is the
question of whether ET-1 acts only as a renal pathogen. Second,
attention to species differences with regard to the renal endothelin
system between experimental animals and humans is crucial
because of the consequences that such differences may have for
disease and for therapeutic approach. Third, we should determine
if ET-1 has a central role among the many known (and unknown)
pathogenetic factors, or whether it plays no more than a sideline
role, since this will determine its pathogenetic relevance. Finally,
it must be kept in mind that functional effects of ET receptor
blockers should also result in better kidney survival.
It is important to consider whether an activated intrarenal
endothelin system has only deleterious actions. In normal kidneys
ET-1 immunoreactivity is largely confined to the vascular and
glomerual endothelium, whereas there is no ET-1 present in the
tubules [12]. However, tubular ET-1 production can be induced in
vitro by ischemia. Ong et a! showed in cultured human proximal
tubule cells that such ET-1 production is amplified through
activation of tubular ETh receptors [90]. Activation of these
tubular ETh receptors also stimulates mitogenesis, which may
contribute to tubular regeneration after ischemia. This would
suggest a protective role for ET-1 and ETh-receptor activation in
some forms of renal disease. The relevance of this hypothesis is
supported by in vivo observations in the dogs, where moderate
hypoxia also resulted in increased ET-1 immunostaining in prox-
imal and distal tubules. This concurred with increased urinary
ET-1 excretion and fractional sodium excretion [91], suggesting
that ET-1 may also play a role in sodium and water homeostasis
under these conditions. In agreement, ET-1 could inhibit Na-K-
ATPase in proximal tubules and decrease 02 consumption in
inner medullary collecting duct cells [31]. ClaveIl et al showed that
these effects of ET-1 in the dog are also mediated through
activation of the ETh receptor: intrarenal infusion of ET-1 in dogs
caused vasoconstriction and sodium retention, whereas ET-1
infusion in the presence of the ETa receptor blocker BQ 123, thus
allowing selective stimulation of the ETh receptor, had no effects
on renal hemodynamics and resulted in diuresis and natriuresis
[92]. Such studies suggest that under certain conditions, such as
ischemia, ET-1 may also serve as a compensatory system to
maintain sodium and water excretion, and favors tubular regen-
eration. The relevance of such potential actions of the ET system
is underscored by observations that the renal medullary ETh and
not the vascular ETa receptor is up-regulated in experimental
models of glomerulonephritis, hypertension, cyclosporine ne-
phropathy and liver cirrhosis [93—96]. Indeed, combined ETa/ETb
receptor blockade in experimental liver cirrhosis resulted in
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impaired water excretion, which is an unwanted side effect in the
clinical setting of this condition [961.
Regarding the function of the ET receptor subtypes, important
species differences probably exist. In rats the ETb receptor
appeared to be crucial in mediating the renal vasoconstrictive
effects of ET-1 [97—99], whereas in the dog ET-mediated vaso-
constriction was ETa receptor dependent [92]. Such differences
may explain why sometimes the combined ETa/ETh receptor
blockade is more effective in rat models of renal disease than
selective ETa receptor blockade. In humans ETh receptors may
mediate vasoconstriction in some vascular beds [100, 1011. How-
ever, the human kidney probably is not subject to important ETh
receptor mediated vasoconstriction, since infusion of the selective
ETh receptor agonist ET-3, in an equimolar amount to dosages of
ET-1 that cause profound renal vasoconstriction, has no effect on
renal perfusion [1021. In these normal subjects ET-3 infusion had
no effects on sodium and water excretion. However, this does not
exclude such actions in disease states. Taken together, these data
cannot identify an important constrictor action of ETb receptor
activation in the normal human kidney, while there are experi-
mental indications that under certain conditions ETh-receptor
blockade could be harmful. This underscores the need for further
information on the role of the ETh-receptor in human renal
disease when applying ET-receptor blockers clinically. This is also
of relevance for conditions such as heart failure, which has
currently been indentified as a major target for ET-receptor
antagonists development [103].
The specificity of the endothelin as a renal pathogen also
remains to be established. Renal disease is a multifactorial
process. For example, development of acute renal failure involves
important mechanisms such as ATP depletion, cellular calcium
overload and reperfusion injury [104, 105]. It is feasible that the
renal vasodilator actions of ET-receptor blockade can ameliorate
part of the ischemic component of acute renal failure. However,
calcium channel blockers can also reverse and largely prevent
ET-1-induced renal vasoconstriction in humans [29, 106, 107]. In
addition these drugs may also have effects on the other mecha-
nisms involved in the pathogenesis of acute renal failure [1081.
When considering the pathophysiological actions of ET-1 as a
cytokine, one has to realize that multiple interactions also exist
between endothelin and other renal growth factors such as PDGF,
vasopressin, fibroblast growth factor and epidermal growth factor
[78, 109—112]. The hierarchical role of endothelin within this
complex is still unknown. This is of great importance to evaluate
its pathogenetic role. If endothelin would be a downstream
effector molecule of other vasoactive peptides or cytokines, then
inhibition of endothelin may also ameliorate the pathogenic
actions of such factors. In favor of this possibility, the hypertro-
phic effects of angiotensin II in cardiac myocytes could be
modulated by endothelin-receptor blockade [113]. One study
recently reported that the endothelin blockade could reduce the
proliferative actions of PDGF on mesangial cells, indeed suggest-
ing a more central role for ET-1 in the development of renal
fibrosis [110]. However, currently this central role for ET-1 in
renal fibrosis in vivo remains to be established. Such information
may not only help to define the pathogenetic potential of endo-
thelin, but may also help to indentify conditions apart from
primarily elevated plasma endothelin levels that may benefit from
endothelin receptor blockade (such as, such as activation of the
renin-angiotensin II system).
Finally, most of the preclinical studies, and also the few human
data that are available, focus on acute changes in renal hemody-
namics in acute experimental conditions, as artificial end points.
Although such studies may be of relevance for the pathophysiol-
ogy of acute renal failure, they do not reflect the pathophysiolog-
ical mechanisms involved in most renal diseases, where renal
outcome is more likely to be determined by structural damage.
Although renal hemodynamic dysfunction and renal fibrosis are
linked in many different ways, and changes in renal perfusion
often precede or contribute to development of structural damage,
there may also be dissociations between hemodynamic changes
and structural damage. This was recently shown in chronic
cyclosporine nephrotoxicity, an outstanding example of renal
injury in which ET-1 has been incriminated in the pathogenesis
[3]. During chronic administration of cyclosporine, both ETa and
combined ETa/ETh blockade could still ameliorate glomerular
dysfunction [114, 1151. Nevertheless, structural damage such as
tubular dilation and vacuolization and arteriolopathy did not
change, while tubulointerstitial fibrosis even worsened during the
endothelin blockade [114, 1151. Such data underscore the neces-
sity of evaluating the potential of endothelin receptor blockers to
prevent structural renal damage and improve (renal) survival in
models of chronic progressive renal disease.
Conclusion
Endothelin is probably a two-edged sword to the kidney. On the
one hand it may contribute to renal injury through its actions as a
vasoconstrictor and cytokine. On the other hand it may also act as
a counterregulatory mechanism serving the maintenance of renal
tubular function. Clearly, more information is needed on the
relative contributions of these dual actions of ET-1 in renal
disease and the ET receptor subtypes involved before applying ET
receptor blockers in human renal disease. In view of the species
differences with regards to the renal endothelin system, further
research on this issue should be focused on the human kidney.
The experimental studies thus far have also made clear that the
putative effects of the ET receptor blockade on structural renal
injury rather than the hemodynamic actions will determine the
clinical value of these drugs in renal medicine. Finally, it may be
relevant to focus future studies in this field on the potential
additional benefits of ET receptor antagonists to standard drugs
such as ACE-inhibitors and calcium channel blockers.
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